Aller au contenu

WP3 Oncology imaging


Local therapies, e.g., thermo-ablation, are already used in clinical practice since they provide similar efficacy to conventional surgery but allow faster recovery time for the patient (a few days compared to several weeks). Moreover, redo procedures can be performed without cumulative effect on healthy tissue as in radiotherapy. However, they lack two significant features: real-time quantitative monitoring of 3D temperature distribution during the treatment to ensure the precise and controlled effect ; and thermo-ablation devices that allow precise 3D conformal heat deposition. Current clinical procedures thus remain restricted to small tumors (3 cm diameter) to avoid compromising efficacy or safety.

In this context, the WP 3 aims to:
  1. refine current methods (WP3-1) 
  2. develop a new high-risk, high-reward strategy in combination with chemical compounds (WP3-2). 
  3. predict the treatment response immediately after therapy to optimize patient care (WP3-3).

WP3-1: Developing dedicated instruments for local delivery of heat (laser and high intensity focused ultrasound) combined with real-time MRI-thermometry

  • General objectives – to develop a set of therapeutic instruments, imaging, and real-time temperature monitoring technologies adapted to clinical applications ; to evaluate these technologies pre-clinically and clinically.
  • WP leaders – Bruno Quesson, Valéry Ozenne, Emeline Ribot (CRMSB) ; Guillaume Machinet (ALPHANOV) ; Stéphane Chemouny (CERTIS Therapeutics)
  • PhD candidate – Fanny Dabrin (supervisor : Bruno Quesson)

WP3-2: Developing drug which release can be physically activated

  • General objectives – to develop therapeutic agents (anti-cancer drugs: doxorubicin, temozolide…, and immunologic agents: PD-L1 antibodies…) encapsulated in nano-carriers sensitive to external physical stimuli (temperature/light) triggering their local release. Once synthesized, their release will be monitored in vivo with the image-guided technologies developed in WP3-1.
  • WP leaders – Olivier Sandre, Sébastien Lecommandoux (LCPO) ; Frédéric Friscourt, Mireille Blanchard-Desce, Philippe Hermange (ISM) ; Stéphane Mornet (ICMCB)
  • PhD candidate – Justine Couvez (supervisors : Mireille Blanchard-Desce/Olivier Sandre)

WP3-3 : Combing imaging and radiomics analysis to assess tumor response with AI-based methods

  • General objectives – To leverage the expertise of imaging biomarker clinicians to identify new features specific to target diseases and treatment. The objective is to find ways to overcome pitfalls such as data scarcity, uncertainties and variability (noise, inter-patient variability, reproducibility with respect to various devices, acquisition parameters and operators) to ultimately develop robust methods that can be deployed in the clinic.
  • WP leaders – Amandine Crombé, Olivier Saut (IMB, MONC) ; Nicolas Grenier (CHU) ; Jean Palussière (Comprehensive Cancer Center Bergonié)
  • PhD candidateEn cours de recrutement 

Research staff